company background image

BioPharma Credit LSE:BPCR Stock Report

Last Price


Market Cap







23 May, 2022


Company Financials
BPCR fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance3/6
Financial Health6/6

BPCR Stock Overview

BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets.

BioPharma Credit Competitors













Price History & Performance

Summary of all time highs, changes and price drops for BioPharma Credit
Historical stock prices
Current Share PriceUS$0.98
52 Week HighUS$1.05
52 Week LowUS$0.94
1 Month Change-0.61%
3 Month Change-4.20%
1 Year Change1.45%
3 Year Change-5.58%
5 Year Change-9.70%
Change since IPO-4.89%

Recent News & Updates

Shareholder Returns

BPCRGB Capital MarketsGB Market

Return vs Industry: BPCR exceeded the UK Capital Markets industry which returned -12.5% over the past year.

Return vs Market: BPCR exceeded the UK Market which returned -4% over the past year.

Price Volatility

Is BPCR's price volatile compared to industry and market?
BPCR volatility
BPCR Average Weekly Movement1.9%
Capital Markets Industry Average Movement4.9%
Market Average Movement6.0%
10% most volatile stocks in GB Market11.6%
10% least volatile stocks in GB Market3.1%

Stable Share Price: BPCR is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: BPCR's weekly volatility (2%) has been stable over the past year.

About the Company


BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in Exeter, the United Kingdom.

BioPharma Credit Fundamentals Summary

How do BioPharma Credit's earnings and revenue compare to its market cap?
BPCR fundamental statistics
Market CapUS$1.35b
Earnings (TTM)US$84.96m
Revenue (TTM)US$103.88m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BPCR income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$103.88m
Other ExpensesUS$18.92m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)0.062
Gross Margin100.00%
Net Profit Margin81.79%
Debt/Equity Ratio0.0%

How did BPCR perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is BioPharma Credit undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: BPCR ($0.98) is trading below our estimate of fair value ($1.34)

Significantly Below Fair Value: BPCR is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: BPCR is poor value based on its PE Ratio (15.9x) compared to the UK Capital Markets industry average (9.3x).

PE vs Market: BPCR is poor value based on its PE Ratio (15.9x) compared to the UK market (15.4x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BPCR's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BPCR is good value based on its PB Ratio (1x) compared to the GB Capital Markets industry average (1.2x).

Future Growth

How is BioPharma Credit forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Diversified Financials industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioPharma Credit has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has BioPharma Credit performed over the past 5 years?

Past Performance Score


Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BPCR has high quality earnings.

Growing Profit Margin: BPCR's current net profit margins (81.8%) are higher than last year (81%).

Past Earnings Growth Analysis

Earnings Trend: BPCR's earnings have grown by 7.2% per year over the past 5 years.

Accelerating Growth: BPCR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BPCR had negative earnings growth (-4.7%) over the past year, making it difficult to compare to the Capital Markets industry average (62.1%).

Return on Equity

High ROE: BPCR's Return on Equity (6.2%) is considered low.

Financial Health

How is BioPharma Credit's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: BPCR's short term assets ($104.7M) exceed its short term liabilities ($6.3M).

Long Term Liabilities: BPCR's short term assets ($104.7M) exceed its long term liabilities ($558.0K).

Debt to Equity History and Analysis

Debt Level: BPCR is debt free.

Reducing Debt: BPCR has not had any debt for past 5 years.

Debt Coverage: BPCR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BPCR has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet


What is BioPharma Credit current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: BPCR's dividend (7.13%) is higher than the bottom 25% of dividend payers in the UK market (1.8%).

High Dividend: BPCR's dividend (7.13%) is in the top 25% of dividend payers in the UK market (4.86%)

Stability and Growth of Payments

Stable Dividend: BPCR has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: BPCR's dividend payments have increased, but the company has only paid a dividend for 5 years.

Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (113.2%), BPCR's dividend payments are not well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (99.7%), BPCR's dividend payments are not well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


BioPharma Credit has no CEO, or we have no data on them.

Board Members

Experienced Board: BPCR's board of directors are considered experienced (5.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

BioPharma Credit PLC's employee growth, exchange listings and data sources

Key Information

  • Name: BioPharma Credit PLC
  • Ticker: BPCR
  • Exchange: LSE
  • Founded: 2016
  • Industry: Asset Management and Custody Banks
  • Sector: Diversified Financials
  • Implied Market Cap: US$1.349b
  • Shares outstanding: 1.37b
  • Website:


  • BioPharma Credit PLC
  • 51 New North Road
  • Exeter
  • Devon
  • EX4 4EP
  • United Kingdom


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/23 00:00
End of Day Share Price2022/05/23 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.